Form HLTH5482 Pharmacare Special Authority Request - Alemtuzumab (Lemtrada) for Multiple Sclerosis - British Columbia, Canada

Form HLTH5482 is a request form for the special authorization of Alemtuzumab (Lemtrada), a medication used for the treatment of Multiple Sclerosis in the province of British Columbia, Canada. It is used by healthcare providers to seek approval for their patients to access this medication through the Pharmacare program.

The Form HLTH5482 Pharmacare Special Authority Request - Alemtuzumab (Lemtrada) for Multiple Sclerosis in British Columbia, Canada is typically filed by the healthcare provider or the prescribing physician.

Form HLTH5482 Pharmacare Special Authority Request - Alemtuzumab (Lemtrada) for Multiple Sclerosis - British Columbia, Canada - Frequently Asked Questions (FAQ)

Q: What is the HLTH5482 Pharmacare Special Authority Request? A: The HLTH5482 Pharmacare Special Authority Request is a form used in British Columbia, Canada to request coverage for the drug Alemtuzumab (Lemtrada) for the treatment of Multiple Sclerosis.

Q: What is Alemtuzumab (Lemtrada)? A: Alemtuzumab (Lemtrada) is a medication used to treat Multiple Sclerosis, a chronic autoimmune disease affecting the central nervous system.

Q: What is Multiple Sclerosis? A: Multiple Sclerosis is a chronic autoimmune disease in which the immune system mistakenly attacks the protective covering of nerve fibers in the central nervous system.

Q: Who can use Alemtuzumab (Lemtrada)? A: Alemtuzumab (Lemtrada) is approved for use in adults with relapsing forms of Multiple Sclerosis who have not responded well to other treatments.

Q: How does the HLTH5482 Pharmacare Special Authority Request work? A: The HLTH5482 Pharmacare Special Authority Request is used to request coverage for Alemtuzumab (Lemtrada) by providing information about the patient's condition and treatment history.

Q: Is Alemtuzumab (Lemtrada) covered by Pharmacare in British Columbia? A: Coverage for Alemtuzumab (Lemtrada) in British Columbia is determined through the special authority process, and approval is subject to meeting specific criteria.